Global superbug response needs $5bn each year, experts predict

Efforts to tackle drug-resistant infections will require a global fund of at least $5 billion each year, researchers have projected. Experts in infectious diseases are calling for a World Bank Trust Fund to coordinate global action on this growing public health crisis. Growing resistance is leading to the emergence of superbugs that can cause life-threatening infections, such as MRSA or drug-resistant tuberculosis.

Researchers say that tackling the problem will require a coordinated global response and recommend introducing targets to reduce the number of drug-resistant infections over the next five years.

$5 billion is needed annually to develop global systems for monitoring resistance and to establish the framework needed to address the threat, experts add.

It could also be used to accelerate the development of new vaccines, diagnostics and treatments, as well as regulatory processes to ensure that current medicines are being used appropriately.

In addition to financial investment, the group proposes global limits on antibiotics use. In particular, use of antibiotics in agriculture to promote growth of farmed animals should be phased out worldwide, they argue.

Improving access to clean water, sanitation and public health infrastructure will help to curb the spread of disease and reduce the overall need for antibiotics, they say.

Researchers from the US Centre for Disease Dynamics, Economics and Policy, the University of Edinburgh, New York University and Fudan University in China outlined their proposals in the journal Science.

Their recommendations come ahead of a United Nations General Assembly meeting in September, where heads of state from around the world will discuss how best to preserve global access to effective medicines for infectious diseases.

Professor Mark Woolhouse, of the University of Edinburgh’s Centre for Immunity, Infection and Evolution, said: “Drug resistance knows no borders, as we have seen with the spread of superbugs around the world. It is crucial that nations come together with appropriate financing and governance to tackle this challenge together.”

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...